Search Results

There are 24835 results for: content related to: A Role for Noradrenergic Transmission in the Actions of Phencyclidine and the Antipsychotic and Antistress Effects of mGlu2/3 Receptor Agonists

  1. You have free access to this content
    Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine

    British Journal of Pharmacology

    Volume 160, Issue 2, May 2010, Pages: 389–398, Neil Benson, Nelleke Snelder, Bart Ploeger, Carolyn Napier, Harriet Sale, Nigel JM Birdsall, Richard P Butt and Piet H van der Graaf

    Version of Record online : 3 MAR 2010, DOI: 10.1111/j.1476-5381.2010.00719.x

  2. Lack of effect of reboxetine on cardiac repolarization

    Clinical Pharmacology & Therapeutics

    Volume 70, Issue 3, September 2001, Pages: 261–269, Joseph C. Fleishaker, Steven F. Francom, Beth D. Herman, Dean W. Knuth and Nkechi E. Azie

    Version of Record online : 27 SEP 2001, DOI: 10.1067/mcp.2001.117705

  3. You have free access to this content
    The Selective Norepinephrine Reuptake Inhibitor Antidepressant Reboxetine: Pharmacological and Clinical Profile

    CNS Drug Reviews

    Volume 10, Issue 1, March 2004, Pages: 23–44, Mihály Hajós, Joseph C. Fleishaker, Jacqueline K. Filipiak-Reisner, Mark T. Brown and Erik H. F. Wong

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2004.tb00002.x

  4. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans

    Clinical Pharmacology & Therapeutics

    Volume 66, Issue 4, October 1999, Pages: 374–379, Beth D. Herman, Joseph C. Fleishaker and Mark T. Brown

    Version of Record online : 14 OCT 1999, DOI: 10.1053/cp.1999.v66.a101207

  5. The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans

    Clinical Pharmacology & Therapeutics

    Volume 90, Issue 2, August 2011, Pages: 246–255, CM Hysek, LD Simmler, M Ineichen, E Grouzmann, MC Hoener, R Brenneisen, J Huwyler and ME Liechti

    Version of Record online : 15 JUN 2011, DOI: 10.1038/clpt.2011.78

  6. You have free access to this content
    Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize α2-adrenoceptors in the prefrontal cortex

    British Journal of Pharmacology

    Volume 132, Issue 1, January 2001, Pages: 183–188, R W Invernizzi, S Parini, G Sacchetti, C Fracasso, S Caccia, K Annoni and R Samanin

    Version of Record online : 29 JAN 2009, DOI: 10.1038/sj.bjp.0703821

  7. Absolute bioavailability of reboxetine enantiomers and effect of gender on pharmacokinetics

    Biopharmaceutics & Drug Disposition

    Volume 20, Issue 1, January 1999, Pages: 53–57, Joseph C. Fleishaker, Massimiliano Mucci, Cinzia Pellizzoni and Italo Poggesi

    Version of Record online : 14 APR 1999, DOI: 10.1002/(SICI)1099-081X(199901)20:1<53::AID-BDD157>3.0.CO;2-P

  8. You have free access to this content
    Paroxetine versus other anti-depressive agents for depression

    Intervention Review

    The Cochrane Library

    Marianna Purgato, Davide Papola, Chiara Gastaldon, Carlotta Trespidi, Laura R Magni, Carla Rizzo, Toshi A Furukawa, Norio Watanabe, Andrea Cipriani and Corrado Barbui

    Published Online : 3 APR 2014, DOI: 10.1002/14651858.CD006531.pub2

  9. Separation of reboxetine enantiomers by means of capillary electrophoresis

    ELECTROPHORESIS

    Volume 23, Issue 12, No. 12 June 2002, Pages: 1870–1877, Maria A. Raggi, Roberto Mandrioli, Cesare Sabbioni, Carlo Parenti, Giuseppe Cannazza and Salvatore Fanali

    Version of Record online : 2 JUL 2002, DOI: 10.1002/1522-2683(200206)23:12<1870::AID-ELPS1870>3.0.CO;2-R

  10. Hemodynamic effects of reboxetine in healthy male volunteers

    Clinical Pharmacology & Therapeutics

    Volume 66, Issue 3, September 1999, Pages: 282–287, Thierry Denolle, Cinzia Pellizzoni, M. Gabriella Jannuzzo and Italo Poggesi

    Version of Record online : 26 SEP 1999, DOI: 10.1016/S0009-9236(99)70036-6

  11. Reboxetine: tolerability and safety profile in patients with major depression

    Acta Psychiatrica Scandinavica

    Volume 101, Issue s402, June 2000, Pages: 37–40, Lars Tanum

    Version of Record online : 22 OCT 2003, DOI: 10.1034/j.1600-0447.2000.02606.x

  12. You have free access to this content
    The antidepressants citalopram and reboxetine reduce seizure frequency in rats with chronic epilepsy

    Epilepsia

    Volume 53, Issue 5, May 2012, Pages: 870–878, Katia Vermoesen, Ann Massie, Ilse Smolders and Ralph Clinckers

    Version of Record online : 16 MAR 2012, DOI: 10.1111/j.1528-1167.2012.03436.x

  13. Reboxetine, a selective noradrenaline reuptake inhibitor, is non-sedative and does not impair psychomotor performance in healthy subjects

    Human Psychopharmacology: Clinical and Experimental

    Volume 13, Issue 6, August 1998, Pages: 425–433, Werner M. Herrmann and Hermann Fuder

    Version of Record online : 21 DEC 1998, DOI: 10.1002/(SICI)1099-1077(199808)13:6<425::AID-HUP17>3.0.CO;2-R

  14. You have free access to this content
    Studies on the acute and chronic effects of reboxetine on extracellular noradrenaline and other monoamines in the rat brain

    British Journal of Pharmacology

    Volume 128, Issue 6, November 1999, Pages: 1332–1338, G Sacchetti, M Bernini, A Bianchetti, S Parini, R W Invernizzi and R Samanin

    Version of Record online : 30 JAN 2009, DOI: 10.1038/sj.bjp.0702926

  15. Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations

    Human Psychopharmacology: Clinical and Experimental

    Volume 13, Issue S1, February 1998, Pages: S29–S39, T. A. Ban, P. Gaszner, E. Aguglia, R. Batista, A. Castillo, A. Lipcsey, J.-P. Macher, A. Torres-Ruiz and L. Vergara

    Version of Record online : 21 DEC 1998, DOI: 10.1002/(SICI)1099-1077(199802)13:1+<S29::AID-HUP980>3.0.CO;2-D

  16. You have free access to this content
    The Promises and Pitfalls of Reboxetine

    CNS Drug Reviews

    Volume 9, Issue 4, December 2003, Pages: 327–342, Michelle E. Page

    Version of Record online : 7 JUN 2006, DOI: 10.1111/j.1527-3458.2003.tb00258.x

  17. Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons

    European Journal of Neuroscience

    Volume 13, Issue 11, June 2001, Pages: 2077–2087, Steven T. Szabo and Pierre Blier

    Version of Record online : 20 DEC 2001, DOI: 10.1046/j.0953-816x.2001.01583.x

  18. PHARMACOKINETICS OF REBOXETINE IN HEALTHY VOLUNTEERS. SINGLE AGAINST REPEATED ORAL DOSES AND LACK OF ENZYMATIC ALTERATIONS

    Biopharmaceutics & Drug Disposition

    Volume 17, Issue 7, October 1996, Pages: 623–633, C. Pellizzoni, I. Poggesi, N. P. Jørgensen, D. M. F. Edwards, E. Paus and M. Strolin Benedetti

    Version of Record online : 4 DEC 1998, DOI: 10.1002/(SICI)1099-081X(199610)17:7<623::AID-BDD978>3.0.CO;2-S

  19. The human pharmacology of reboxetine

    Human Psychopharmacology: Clinical and Experimental

    Volume 13, Issue S1, February 1998, Pages: S3–S12, E. Szabadi, C. M. Bradshaw, P. F. Boston and R. W. Langley

    Version of Record online : 21 DEC 1998, DOI: 10.1002/(SICI)1099-1077(199802)13:1+<S3::AID-HUP981>3.0.CO;2-O

  20. Reboxetine: its effects as measured by the Social Adaptation Self-evaluation Scale

    Acta Psychiatrica Scandinavica

    Volume 101, Issue s402, June 2000, Pages: 45–51, David Healy

    Version of Record online : 22 OCT 2003, DOI: 10.1034/j.1600-0447.2000.02608.x